Survival rates for patients with pulmonary hypertension (PH) remain low, and our understanding of the mechanisms involved are incomplete. Here we show in a mouse model of chronic hypoxia (CH)-induced PH that the nuclear protein and damageassociate molecular pattern molecule (DAMP) high mobility group box 1 (HMGB1) contributes to PH via a Toll-like receptor 4 (TLR4)-dependent mechanism. We demonstrate extranuclear HMGB1 in pulmonary vascular lesions and increased serum HMGB1 in patients with idiopathic pulmonary arterial hypertension. The increase in circulating HMGB1 correlated with mean pulmonary artery pressure. In mice, we similarly detected the translocation and release of HMGB1 after exposure to CH. HMGB1-neutralizing antibody attenuated the development of CH-induced PH, as assessed by measurement of right ventricular systolic pressure, right ventricular hypertrophy, pulmonary vascular remodeling and endothelial activation and inflammation. Genetic deletion of the pattern recognition receptor TLR4, but not the receptor for advanced glycation end products, likewise attenuated CH-induced PH. Finally, daily treatment of mice with recombinant human HMGB1 exacerbated CH-induced PH in wild-type (WT) but not Tlr4 -/-mice. These data demonstrate that HMGB1-mediated activation of TLR4 promotes experimental PH and identify HMGB1 and/or TLR4 as potential therapeutic targets for the treatment of PH.
INTRODUCTION
Pulmonary hypertension (PH) is a devastating disease characterized by a sustained increase in pulmonary arterial pressure. This increase in pressure is primarily due to vasoconstriction and remodeling of small pulmonary arteries, resulting in increased pulmonary vascular resistance, right ventricular failure and ultimately death. PH can be idiopathic, familial, associated with connective tissue disease or a result of drug or toxin exposure (1) . Patients with these various forms of PH exhibit similar clinical, functional and hemodynamic characteristics and poor survival (2) (3) (4) (5) .
Recently, the development of therapies for the management of PH has focused on promoting vasodilation (6) . While use of drugs promoting vasodilation leads to improvements in functional capacity and modest decreases in pulmonary artery pressure, recent metaanalysis of controlled trials using these agents demonstrated only limited benefit in terms of mortality (7, 8) .
One significant barrier to the treatment of PH is the relative lack of understanding of the role of immune mechanisms in the development and progression of the disease. Over the past decade, a new class of proinflammatory molecules, termed damage-associated molecular pattern molecules (DAMPs), has emerged as important inflammatory mediators (9) . DAMPs are endogenous molecules, ranging from proteins to small molecules, that are actively secreted or passively released by damaged cells. Once in the extracellular milieu, DAMPs promote inflammation and tissue repair. 
High Mobility Group Box 1 Contributes to the Pathogenesis of Experimental Pulmonary Hypertension via Activation of Toll-like Receptor 4
High mobility group box 1 (HMGB1) is a prototypical and highly conserved DAMP. Under normal conditions, HMGB1 is a nuclear protein, where it functions to stabilize nucleosomes (10) . However, on release into the extracellular environment, HMGB1 acts as a proinflammatory cytokine by activating pattern recognition receptors (PRRs), including Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE) (11) (12) (13) . Evidence suggests that in response to persistent tissue injury, HMGB1, via activation of PRRs, acts as a key initiating molecule of innate immunity, orchestrating inflammation, stem cell recruitment/activation and tissue remodeling (13) . Herein, we examined the role of HMGB1, TLR4 and RAGE in the development of chronic hypoxia (CH)-induced PH in mice.
MATERIALS AND METHODS

Human Subjects
Human tissue was obtained in compliance with University of Pittsburgh and Cleveland Clinic Institutional Review Board guidelines.
Animal Use
All animal procedures were carried out in accordance with the guidelines set by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) and with IACUC approval.
Mice
C57BL/6J mice were purchased from The Jackson Laboratory. Tlr4 -/-mice and Rage -/-mice were generated on a C57BL/6J background as previously described (14, 15) . Age-matched 8-to 12-wkold male mice were used for the studies.
Cell Culture
Human pulmonary artery endothelial cells (HPAECs), human pulmonary artery smooth muscle cells (HPASMCs) and cell media were from Lonza. For experiments, HPAECs were serumstarved overnight, and HPASMCs were serum-starved for 24 h in minimal media. Cells were used between passage 4 and 9.
Materials
Mouse anti-human TLR4 neutralizing antibody and nonimmune mouse IgG were from eBioscience (San Diego, CA, USA). Polyclonal antibody against HMGB1 (provided by Kevin Tracey, North Shore-Long Island Jewish Health System, Feinstein Institute for Medical Research) was prepared as described previously (16) . Neutralizing activity of anti-HMGB1 was confirmed in HMGB1-stimulated macrophage cultures by assay of tumor necrosis factor (TNF) release. In the presence of anti-HMGB1 antibody, neutralizing antibody was defined as inhibiting >80% of HMGB1-induced TNF release. Nonimmune rabbit IgG was purchased from Sigma-Aldrich. For Western blots, antibody against HMGB1 (#3935) was from Cell Signaling Technology (Danvers, MA, USA).
HMGB1 Isolation and Purification
The His-tagged full-length cDNA for human HMGB1 subcloned into the secretion signal of the FLAG expression vector YEpFLAG (Sigma) was transformed into the protease-deficient yeast strain BJ3505. The yeast was propagated, and HIS-tagged HMGB1 was purified as previously described (17) . After purification, the protein was dialyzed versus 25 mmol/L Tris, 150 mmol/L KCl (pH 8.0), aliquoted and snap frozen at -80°C.
Hypoxic Exposure and Physiologic Measurements
Mice were exposed to CH (10% O 2 ) for the indicated times, with normoxic mice serving as control. Right ventricular systolic pressure (RVSP) was measured essentially as described (18) . Briefly, mice were anesthetized with sodium pentobarbital (60 mg/kg intraperitoneally [IP] ) and ventilated via tracheotomy with room air (175 breaths per minute, 175 μL tidal volume). Body temperature was monitored and regulated with a rectal probe and heating pad. RVSP was determined by placing a 1 F solid-state pressure transducing catheter (Millar Instruments, Houston, TX, USA) directly into the right ventricle (RV). Data were acquired by using a PowerLab data acquisition system and LabChart Pro software (AD Instruments). Blood was collected via cardiac puncture. Bronchoalveolar lavage (BAL) was obtained by washing the lung via the trachea three times with 0.5 mL phosphate-buffered saline (PBS). The vasculature was flushed with PBS, the heart was excised and right heart hypertrophy was determined by the ratio of the weight of the RV to the left ventricle (LV) plus septum (Fulton index). The right lung was tied off, dissected and flash frozen, and the left lung was perfused with paraformaldehyde (4%) for embedding into paraffin.
Immunohistochemistry
Paraffin-embedded lung sections (5 μm) were baked 60 min at 55°C, deparaffinized in xylenes and rehydrated through decreasing alcohol concentrations (three xylenes, 2× 100%, 1× 95%, 1× 90%, 1× 70% ethanol, 1× PBS, for 3 min each) followed by antigen retrieval citrate buffer by using a microwave. Smooth muscle α-actin staining was performed as described (18) . For immunofluorescent staining, sections were blocked in 2% bovine serum albumin after antigen retrieval and then incubated in anti-HMGB1 antibody overnight, followed by incubation for 60 min with a secondary antibody (Cy3). Nuclei were counterstained with Hoechst dye. Images were taken by using an Olympus Fluoview 1000 confocal microscope in the Center for Biological Imaging at the University of Pittsburgh.
Assessment of Pulmonary Vascular Remodeling
Pulmonary vascular remodeling was assessed by counting the number of partially and fully muscularized peripheral arterioles (35-100 mm) per high-power field (200× total magnification). For each mouse, at least 20 high-power fields were analyzed in multiple lung sections. Wall thickness of muscularized vessels was determined by measuring the thickness at four points on pulmonary arterioles by using the Java-based image-processing program ImageJ (National Institutes of Health, Bethesda, MD, USA).
Enzyme-Linked Immunosorbent Assay
The mouse endothelin 1 (ET-1) and mouse soluble intracellular adhesion molecule 1 (sICAM) enzyme-linked immunosorbent assays (ELISAs) were from R&D Systems (Minneapolis, MN, USA) and were performed according to the manufacturer's instructions. The human HMGB1 ELISA was from IBL International (Hamburg, Germany) and was performed according to the manufacturer's instructions.
Western Blot
Lung homogenate, serum or BAL (BAL was centrifuged before loading to remove contaminating cells) was separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Membranes were blocked in Tris-buffered saline, 0.1% Tween 20 (TBST), and 5% nonfat dry milk for 30 min, followed by incubation in primary antibody overnight. Membranes were washed in TBST before incubation for 1 h with horseradish peroxidaseconjugated secondary antibodies. Membranes were washed and developed by using enhanced chemiluminescence substrate (Pierce).
Cell Proliferation
Proliferation of HPASMCs was determined by measuring [ 3 H] incorporation as previously described (18) . Briefly, cells were serum-starved for 24 h in 12-well plates and treated with either 1 μg/mL recombinant human HMGB1 with or without platelet-derived growth factor (PDGF) (10 ng/mL, Sigma P4056) for 24 h. During the last 16 h, 0.2 μCi [ 3 H]thymidine was added. After the incubation period, cells were washed twice with ice-cold PBS, and 1 mL ice-cold 10% trichloroacetic acid (Sigma T0699) was added to each well for a 30-min incubation at 4°C, after which each well was washed with 1 mL ice-cold 10% trichloroacetic acid. To each well, 0.5 mL of 0.4 N NaOH, 0.1% (wt/vol) SDS, was added, and the plates were incubated for 1 h at room temperature. The contents of each well were then transferred to 7-mL scintillation vials containing 4.5 mL PicoFluor-15 scintillation mixture (ICN [now MP Biomedicals, Santa Ana, CA, USA]) and counted in a liquid scintillation spectrometer.
Statistical Analysis
Statistical analyses were performed by using Graphpad Prism software. For human data, idiopathic pulmonary arterial hypertension (IPAH) versus control patient data were analyzed by Student t test with Welch correction. HMGB1 levels were correlated to mean pulmonary artery pressure by the method of Pearson. For mice, data were analyzed by one-way analysis of variance and Bonferroni post hoc tests. P values of <0.05 were considered significant.
All supplementary materials are available online at www.molmed.org.
RESULTS
HMGB1 Release in Human and Experimental PH
To identify a role for HMGB1 in PH, we initially sought to determine whether HMGB1 is mobilized from the nucleus to the extracellular milieu, where it can act as a DAMP. We examined the localization of HMGB1 in the pulmonary arteries of IPAH patients receiving lung transplants (n = 3) or pulmonary arteries from failed donor lungs (control, non-PH). In pulmonary arteries from IPAH patients, we observed extranuclear HMGB1 in concentric and plexiform vascular lesions, whereas HMGB1 showed strict nuclear localization in pulmonary arteries of non-PH patients ( Figure 1A ). An increase in circulating HMGB1 was shown in several inflammatory conditions (19) (20) (21) (22) (23) (24) (25) (26) . We, therefore, measured serum HMGB1 in IPAH patients versus healthy controls. The mean serum HMGB1 con- centration in the serum of IPAH patients was nearly sixfold higher than in healthy controls (33.6 versus 5.7 ng/mL HMGB1) ( Figure 1B ). In addition, we found that in the 16 patients for whom we had hemodynamic data available, circulating HMGB1 levels correlated with mean pulmonary artery pressures ( Figure 1C) . Characteristics of the patient population can be found in Table 1 .
Likewise, by using the mouse model of CH-induced PH (constant exposure to 10% O 2 ), we were able to demonstrate translocation of HMGB1 from the nucleus to the extracellular milieu. In pulmonary arteries from normoxic C57BL/6J mice, HMGB1 was localized to the nucleus. Within 48 h of exposure to hypoxia, we observed translocation of HMGB1 to extranuclear locations (Figure 2A ). The translocation of HMGB1 to extranuclear compartments was associated with increased HMGB1 in the serum ( Figure 2B ) and BAL fluid ( Figure 2C ), demonstrating that HMGB1 is released into the extracellular milieu in response to hypoxia. In addition, we detected an overall increase in HMGB1 expression in lung homogenate in response to CH ( Figure 2D ).
HMGB1 Neutralizing Antibody Attenuates Experimental PH
To study the hemodynamic impact of extracellular HMGB1 in CH-induced PH, we treated C57BL/6J mice exposed to 3 wks of CH with an HMGB1-neutralizing antibody (αHMGB1) or control IgG (50 μg every other day). Untreated normoxic and CH mice served as the baseline for non-PH and CH-induced PH, respectively. As expected, CH induced an increase in RVSP and right ventricular hypertrophy (RVH) in untreated mice. Supporting the hypothesis that extracellular HMGB1 contributes to the pathogenesis of PH, treatment of mice with αHMGB1 significantly attenuated the increase in RVSP and RVH in response to CH ( Figures 3A, B) . Treatment of mice with nonspecific IgG had no effect on the course of CH-induced PH, demonstrating the specificity of the αHMGB1 antibody.
We then investigated the effect of CH on vascular remodeling in these mice by assessing the degree of muscularization of peripheral pulmonary arteries. Increased muscularization was observed in the CH wild-type (WT) mice, as reflected by enhanced immunoreactivity for α-smooth muscle cell actin (SMA). Treatment with αHMGB1, but not control IgG, attenuated pulmonary vascular remodeling. Figures 4A-C show representative photomicrographs of SMA-stained lung sections from hypoxic WT mice and hypoxic WT mice treated with control IgG or αHMGB1, respectively. Morphometric analysis reveals that treating mice with αHMGB1 had no effect on the number of partially muscularized arterioles (Figure 4D) , but led to a decreased number of fully muscularized arterioles (<150 μmol/L) ( Figure 4E ) as well as decreased vessel wall thickness (Figure 4F ) when compared with untreated or IgG-treated CH mice. In vitro experiments reveal that HMGB1 had no effect on human pulmonary artery smooth muscle cell proliferation, suggesting that the effects of HMGB1 on vascular remodeling were indirect ( Figure 4G ). Endothelial dysfunction and inflammation contributes to the development of PH by promoting vasoconstriction and pulmonary vascular remodeling. Several markers of endothelial dysfunction and inflammation are increased in human and experimental PH, including intracellular adhesion molecule 1 (ICAM-1) and ET-1 (27, 28) , and drugs that target ET-1 receptors are used to treat PH (29) . We observed increased lung ICAM-1 and plasma ET-1 in untreated or IgG-treated mice exposed to CH. In CH mice treated with αHMGB1 antibody, the increase in ICAM-1 and ET-1 was abrogated ( Figures 5A, B) , suggesting that HMGB1 contributes to endothelial dysfunction and inflammation in PH.
TLR4 Contributes to the Pathogenesis of PH
HMGB1 is known to bind to and activate both TLR4 and RAGE. There are no data on the role of RAGE in PH, whereas a recent study demonstrated that mice expressing mutant TLR4 (C3H/HEJ mice) are protected from PH. We first examined whether TLR4 or RAGE is upregulated in response to CH. RNA isolated from the lungs of age-matched male C57BL/6J mice exposed to normoxia or 3 wks of CH was reversetranscribed, and RAGE or TLR4 message was assessed by quantitative polymerase chain reaction ( Figure 6A ). TLR4 expression was approximately threefold higher in the lungs of CH mice compared with normoxic mice. RAGE expression was nearly twofold greater; however, the difference was not statistically significant.
To confirm a role for these receptors in the development of PH, WT (C57BL/6J), Rage -/-and Tlr4 -/-mice were exposed to CH for 3 wks. Age-matched mice kept in room air served as controls. The loss of TLR4, but not RAGE, significantly atten- Figure 6C ). SMA staining of lung sections from WT mice revealed an increase in muscularization of arterioles (<150 μmol/L) in hypoxic versus normoxic WT mice. There were significantly less partially and fully muscularized arterioles in the lungs of Tlr4 -/-hypoxic versus WT hypoxic mice ( Figures 6D, E) . In contrast, we observed no difference in partially muscularized vessels in hypoxic Rage -/-versus hypoxic WT mice. The number of fully muscularized vessels in Rage -/-mice tended to be fewer when compared to WT mice, but the difference did not reach statistical significance. Vessel wall thickness was also increased in WT mice in response to CH, and there was no difference between WT and Rage -/-mice.
R E S E A R C H A R T I C L E
When compared with WT mice, however, there was significantly less thickening of pulmonary arterioles in Tlr4 -/-mice ( Figure 6F ). Similarly, genetic deletion of TLR4, but not RAGE, abrogated CH-induced increases in ET-1 and sICAM-1 ( Figures 6G, H) . These data suggest an important role for TLR4, but not RAGE, in the development of PH.
Exogenous HMGB1 Exacerbates CH-Induced PH in a TLR4-Dependent Manner
On the basis of our results demonstrating a role for HMGB1 and TLR4 in the development of PH, we next tested whether the effect of HMGB1 in PH is TLR4 dependent. WT or Tlr4 -/-mice were exposed to CH for 10 d with or without daily injections of recombinant human HMGB1 (10 μg/d IP). In normoxia, HMGB1 had no effect on RVSP, RVH or pulmonary vascular remodeling in WT or Tlr4 -/-mice, with HMGB1 exacerbated CH-induced increases in RVSP and RVH (Figures 7A, B) . Likewise, pulmonary vascular remodeling worsened in WT mice treated with HMGB1, whereas Tlr4 mice were unaffected ( Figures 7C-E) . HMGB1 treatment of hypoxic WT mice also increased plasma ET-1 levels over hypoxia alone without affecting sICAM levels ( Figure 8A ). HMGB1 had no effect on ET-1 or sICAM in Tlr4 -/-mice ( Figure   8B ). Finally, treatment of human pulmonary artery endothelial cells with HMGB1 resulted in a significant increase in ET-1 released into the cell culture media, as determined by ELISA ( Figure  8C ). The effect of HMGB1 on ET-1 release in HPAECs was abrogated by a TLR4-neutralizing antibody demonstrating that the effect was mediated by TLR4. Taken together, these data demonstrate that HMGB1 promotes experimental PH via TLR4. DISCUSSION PH is classically described as a disease of endothelial dysfunction involving pulmonary vasoconstriction and pulmonary vascular remodeling, leading to increased pulmonary vascular resistance. However, clinical data demonstrate that despite advances in therapeutics aimed at promoting pulmonary vasodilation, survival remains poor (30) . These data highlight the necessity of novel approaches to treating PH. There is mounting evidence of a role for the immune system in the pathogenesis of PH. A role for inflammation in human PH is based on the identification of inflammatory cells in vascular lesions of PH patients (31), elevated circulating levels of inflammatory cytokines in PH patients (32) and case studies in PH patients demonstrating improvement with antiinflammatory drugs (33, 34) . In the mouse model of CH-induced PH, there is an influx of inflammatory cells within the first 48 h that diminishes by 2 wks. This increase in inflammatory cells coincides with increased secretion of proinflammatory cytokines, including TNFα, interleukin (IL)-1β, IL-6 and MCP-1 (35) . In addition, IL-6 overexpression promotes, and genetic deletion of IL-6 attenuates, PH in this model (36, 37) .
H M G B 1 P R O M O T E S E X P E R I M E N T A L
A key facet of the innate immune response is self-/nonself recognition.
Through the use of PRRs, the innate immune system is capable of detecting conserved pathogen motifs, termed pathogen-associated molecular patterns (PAMPs), thereby stimulating an immune response (38) . In recent years, however, it was acknowledged that the self-/nonself paradigm fails to explain innate immune activation in diseases involving sterile inflammation (39) . The discovery of DAMPs, which have a similar function to PAMPs, has provided a context for understanding innate immune activation in the absence of foreign pathogens (9) . HMGB1 fulfills the functions of a DAMP, being involved in inflammation caused by both infectious and noninfectious stimuli (40) . Once released, HMGB1 signals through various PRRs to activate immune and parenchymal cells involved in the immune process (11) (12) (13) .
Our studies clearly establish a role for extracellular HMGB1 in the pathogenesis of CH-induced PH in mice. In particular, data showing translocation of HMGB1 into the extracellular milieu and that HMGB1-neutralizing antibody attenuates CH-induced PH show the necessity of extracellular HMGB1 to fully develop the disease. HMGB1 may have additional intracellular roles in PH; however, the strategies used in this study likely do not address these roles. The clinical relevance of these data is indicated by the observations that (a) there is a diffuse extranuclear staining pattern of HMGB1 in pulmonary vascular lesions of PH patients and (b) there is increased circulating HMGB1 in PH patients, which correlates with mean pulmonary arterial pressure.
In addition to our findings in mice and humans, it was also reported, in the form of an a published abstract, that there is increased circulating HMGB1 in monocrotaline rats and that HMGB1 is released from smooth muscle cells and alveolar macrophages in this model (41) . The consistency of this phenomenon (increased circulating HMGB1) across mice, rats and humans suggests that HMGB1 is an important mediator of PH across species. Future studies using similar strategies (that is, HMGB1-neutralizing antibodies) in other experimental PH models, such as monocrotaline and the SU5416/hypoxia model in rats, will be important to support this hypothesis.
A role for HMGB1-TLR4 interaction in driving immunopathology was initially described in 2005. In that study, it was found that an HMGB1-neutralizing anti- (47) . The effect of the HMGB1-neutralizing antibody or genetic deletion of TLR4 on sICAM levels would appear to be indirect, since exogenous HMGB1 did not further increase sICAM. Alternatively, it is possible that sICAM expression is maximally induced by endogenous HMGB1 and cannot be further induced by addition of the exogenous protein.
In addition to its effects on ET-1 and ICAM-1 expression, recent data from our laboratory demonstrate that HMGB1 is a potent inhibitor of endothelial cell migration, suggesting one mechanism may be the inhibition of endothelial repair mechanisms (17) . In addition, in that study, we show that hypoxia induces the release of HMGB1 from endothelial cells, suggesting that endothelial cells could be one source of increased circulating HMGB1 in PH. The HMGB1/TLR4 signaling axis has been shown to stimulate neutrophil NADPH oxidase (NOX2) in both neutrophils and lung microvascular endothelial cells, and NOX2 is thought to be important in the pathogenesis of PH (48) . TLR4 is also expressed on multiple other cell types important in the pathogenesis of PH. HMGB1 induces macrophages to secrete proinflammatory cytokines in a TLR4-dependent manner (49) . Studies also demonstrate that TLR4 is found on platelets and that activation of platelet TLR4 promotes platelet aggregation (50) , which may promote in situ thrombosis, a feature of human IPAH. Future experiments using bone marrow chimeric mice and tissue-specific knockouts will help reveal cell-specific mechanisms by which TLR4/HMGB1 signaling promotes PH.
We also explored the possibility that RAGE contributes to the development of CH-induced PH. RAGE is highly enriched in the lung (51, 52) and has been reported to be a important receptor for HMGB1 (53) (54) (55) . Interestingly Rage -/-mice developed the same degree of PH (as determined by RVSP) as WT mice when exposed to CH, suggesting that RAGE does not contribute to increased pulmonary vascular resistance in CHinduced PH. This was corroborated by data showing that CH induced a similar degree of pulmonary vascular remodeling in WT and Rage -/-mice. Despite these observations, CH-induced RVH was significantly attenuated in Rage -/-mice when compared with WT mice. These data suggest that RAGE is involved in the hypertrophic response of the right heart to increased pulmonary arterial pressure. This result is consistent with a previous study demonstrating a role for RAGE in mediating cardiac hypertrophy in mice fed a Western diet (56) . Whereas the attenuated RVH in Rage -/-mice is an important observation,
